In Vitro and in Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing
Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-13-0966
Full Text
Open PDFAbstract
Available in full text
Date
April 10, 2014
Authors
Publisher
American Association for Cancer Research (AACR)